why is Plus Therapeutics share jumps 80% at Pre

The US Department of Health and Services has approved the company an exceptional $ 4.6 million payment for work it has done in recent years and sends the stock price at an impressive jump.

Pharma Plus Therapeutics announced today that it has received a $ 4.6 million payment from the U.S. Department of Health and Services for work carried out between 2012 and 2019. The company is expected to receive payment as early as next month. 

The report now sends Plus Therapeutics (NYSE: PSTV) stock up about 80% on Wall Street's pre-trade startup, when the company will actually receive a higher than its market value of $ 3.63 million. 

Pharmaceuticals Plus Therapeutics focuses on discovering, developing, and manufacturing complex, innovative therapies for patients battling cancer and other life-threatening diseases.

Our proprietary nanotechnology platform is currently focused on the improved supply of a variety of drugs with new liposomal encapsulation technology as well as new formulations for injectable drugs.

Its main product is the FDA approved DocePLUS in 1999 and is commonly used to treat breast, head, neck, stomach, prostate and lung cancers.